Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed study 3133K1-3001 (Week 78) and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease~* Mini-Mental Status Examination (MMSE) \>=10 at screening~* Caregiver able to attend all clinic visits with subject~Exclusion Criteria:~* Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.~* Any significant brain MRI abnormality.~* Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Bapineuzumab 0.5 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).